Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Karulkar, Atharva; Jain, Hasmukh; Shah, Savan; Khan, Aalia; Jaiswal, Ankesh Kumar; Firfiray, Afrin; Suvasia, Prashant; Suvasia, Priyanshi; Pendhari, Juber; Asija, Sweety; Chowdury, Ambalika; Banik, Ankit; Ravikumar, Smrithi; Sharma, Neha; Poojary, Minal; Hiregoudar, Sumathi; Desai, Preeti; Navkudkar, Anisha; Rajadhyaksha, Sunil; Thorat, Jayashree; Tembhare, Prashant; Nisar, Albeena; Sengar, Manju; Stroncek, David F.; Highfill, Steven L.; Shah, Nirali N.; Narula, Gaurav; Purwar, Rahul

doi:10.1182/blood-2022-168928

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advanced cell engineering enables the incorporation of inducible CAR expression switches to reduce toxicity ( 257 ). New manufacturing platforms reduce the cost and vein-to-vein time, improving the accessibility of CAR-T ( 258 , 259 ). The rapidly evolving field of CAR-based therapy should hopefully deliver products with better efficacy, tolerability and accessibility, broader indication, and less physical and financial toxicity to patients with lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Pang,

Ghosh

2024

Front. Oncol.

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies. Despite the success, treatment failure due to CD19 antigen loss, mutation, or down-regulation remains the main obstacle to cure. On-target, off-tumor effect of CD19-CAR T leads to side effects such as prolonged B-cell aplasia, limiting the application of therapy in indolent diseases such as chronic lymphocytic leukemia (CLL). Alternative CAR targets and multi-specific CAR are potential solutions to improving cellular therapy outcomes in B-NHL. For Hodgkin lymphoma and T-cell lymphoma, several cell surface antigens have been studied as CAR targets, some of which already showed promising results in clinical trials. Some antigens are expressed by different lymphomas and could be used for designing tumor-agnostic CAR. Here, we reviewed the antigens that have been studied for novel CAR-based therapies, as well as CARs designed to target two or more antigens in the treatment of lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Pang,

Ghosh

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Indigenous CAR-T cell technology has been pioneered in India by the Indian Institute of Technology (Mumbai, India) in partnership with the Advanced Centre for Treatment, Research and Education in Cancer (Navi Mumbai, India) 10 . This investigational product has completed early clinical trials 11 . The second investigational product being developed is by Immuneel Therapeutics, which has a CAR-T cell product in collaboration with and licensed from the Hospital Clinic de Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer 12 .…”

Section: Availability and Funding Of Car-t Cell Therapy In Asiamentioning

confidence: 99%

Challenges in Global Access to CAR-T cells: an Asian Perspective

2024

BCT

View full text Add to dashboard Cite

The use of cell therapy for clinical applications has seen a dramatic increase in recent years, primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell therapies. However, there are some barriers to the widespread adoption of CAR-T cell therapies globally, primarily because of the high cost of manufacturing these cells and clinical infrastructure considerations. We reviewed the different strategies adopted across Asia to implement CAR-T cell therapy and found that these included patient assistance programs, close engagement with funders, cost-effectiveness studies, on-site manufacturing of CAR-T cells, and joint ventures between local partners and foreign pharmaceutical companies. Although on-site manufacturing can reduce the cost of genetic engineering and expansion, it does not address many other hidden costs and quality considerations. Future growth in large-scale regional manufacturing, facilitated by cutting-edge science and innovation, could reduce costs through economies of scale and facilitate the eagerly needed global access.

show abstract